Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOB2: Safety of Cystadrops in pediatric cystinosis patients aged 6 months to <2 years
2018-002984-24Phase 3Unknown
- Sponsor
- Recordati SpA
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cysteamine in ocular cystinosis and nephropathic cystinosis, sponsored by Recordati SpA. Primary endpoint: Primary safety endpoint. Status: unknown.
02
Drugs
cysteamine
03
Conditions
ocular cystinosisnephropathic cystinosis
Beyond the preview
Go deeper on 2018-002984-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002984-24.